Gabapentin

Generic Name
Gabapentin
Brand Names
Gralise, Neurontin
Drug Type
Small Molecule
Chemical Formula
C9H17NO2
CAS Number
60142-96-3
Unique Ingredient Identifier
6CW7F3G59X
Background

Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.. It is structurally and functionally related to another GABA derivative, pregabalin.

Indication

In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.

Associated Conditions
Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia
Associated Therapies
-

Gabapentin for Abstinence Initiation in Alcohol Dependence

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-06-10
Last Posted Date
2019-04-24
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
40
Registration Number
NCT01141049
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

🇺🇸

Substance Treatment and Research Service (STARS), New York, New York, United States

Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers

First Posted Date
2010-05-07
Last Posted Date
2011-03-07
Lead Sponsor
Pfizer
Target Recruit Count
19
Registration Number
NCT01119222
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

The Effect of Gabapentin on Thoracic Epidural Analgesia Following Thoracotomy

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-05-05
Last Posted Date
2014-08-05
Lead Sponsor
University of Aarhus
Target Recruit Count
104
Registration Number
NCT01116583
Locations
🇩🇰

Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Skejby, Aarhus N, Denmark

Oral Clonidine & Gabapentin: Improving Recovery and Pain Management After Outpatient With Major Orthopedic Surgery

First Posted Date
2010-04-29
Last Posted Date
2015-09-14
Lead Sponsor
Cedars-Sinai Medical Center
Registration Number
NCT01112878
Locations
🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

Fibromyalgia Treatment Trial With Gabapentin and Osteopathic Manipulative Medicine

First Posted Date
2010-04-21
Last Posted Date
2013-08-28
Lead Sponsor
Good Samaritan Regional Medical Center, Oregon
Target Recruit Count
41
Registration Number
NCT01107574
Locations
🇺🇸

Touro University College of Osteoapathic Medicine, Vallejo, California, United States

Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children

Phase 1
Withdrawn
Conditions
Interventions
First Posted Date
2010-03-25
Last Posted Date
2013-08-20
Lead Sponsor
The Hospital for Sick Children
Registration Number
NCT01092520
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

Stanford Accelerated Recovery Trial (START)

First Posted Date
2010-02-11
Last Posted Date
2022-05-05
Lead Sponsor
Stanford University
Target Recruit Count
422
Registration Number
NCT01067144
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition

Phase 3
Withdrawn
Conditions
Interventions
First Posted Date
2010-01-21
Last Posted Date
2020-10-01
Lead Sponsor
59th Medical Wing
Registration Number
NCT01052896
Locations
🇺🇸

San Antonio Military Medical Center - North, San Antonio, Texas, United States

🇺🇸

San Antonio Military Medical Center - South, San Antonio, Texas, United States

Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy

First Posted Date
2010-01-20
Last Posted Date
2014-03-07
Lead Sponsor
Faculdade de Medicina do ABC
Target Recruit Count
80
Registration Number
NCT01052844
Locations
🇧🇷

Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil

Plasma Gabapentin Concentration During and Following Cardiac Bypass

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-12-01
Last Posted Date
2009-12-08
Lead Sponsor
Queen's University
Target Recruit Count
16
Registration Number
NCT01022736
Locations
🇨🇦

Kingston General Hospital, Kingston, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath